BRAINSTORM CELL THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
BCLI$1.14-7.3%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| · 2023 · 2022 | ||||||
| | U.S. $ in thousands | |||||
| ASSETS | | | ||||
| | | | | | | |
| Current Assets: · · · · | ||||||
| Cash and cash equivalents | | $1,300 | | $772 | ||
| Short-term deposit (Note 8) | | — | | 2,211 | ||
| Other accounts receivable | | 51 | | 91 | ||
| Prepaid expenses and other current assets (Note 4) | | 548 | | 32 | ||
| Total current assets | | $1,899 | | $3,106 | ||
| | | | | | | |
| Long-Term Assets: | | | | | ||
| Prepaid expenses and other long-term assets | | $22 | | $23 | ||
| Restricted Cash | | | 185 | | | — |
| Operating lease right of use asset (Note 5) | | | 1,416 | | | 4,389 |
| Property and Equipment, Net (Note 6) | | 686 | | 933 | ||
| Total Long-Term Assets | | $2,309 | | $5,345 | ||
| | | | | | | |
| Total assets | | $4,208 | | $8,451 | ||
| | | | | | | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | | | | | ||
| | | | | | | |
| Current Liabilities: | | | | | ||
| Accounts payables | | $4,954 | | $6,224 | ||
| Accrued expenses | | 1,240 | | 84 | ||
| Operating lease liability (Note 5) | | | 603 | | | 1,427 |
| Employees related liability | | 1,003 | | 1,065 | ||
| Total current liabilities | | $7,800 | | $8,800 | ||
| | | | | | | |
| Long-Term Liabilities: | | | | | | |
| Operating lease liability (Note 5) | | | 672 | | | 2,666 |
| Warrants liability (Note 9) | | | 594 | | | — |
| Total long-term liabilities | | $1,266 | | $2,666 | ||
| | | | | | | |
| Total liabilities | | $9,066 | | $11,466 | ||
| | | | | | | |
| Stockholders’ Deficit: | | | | | ||
| Stock capital: (Note 10) | | 13 | | 12 | ||
| Common Stock of $0.00005 par value - Authorized: 100,000,000 shares at December 31, 2023 and December 31, 2022 respectively; Issued and outstanding: 60,489,208 and 36,694,078 shares at December 31, 2023 and December 31, 2022 respectively. | | | | | | |
| Additional paid-in-capital | | 210,258 | | 194,910 | ||
| Treasury stocks | | (116) | | (116) | ||
| Accumulated deficit | | (215,013) | | (197,821) | ||
| Total stockholders’ deficit | | $(4,858) | | $(3,015) | ||
| | | | | | | |
| Total liabilities and stockholders’ deficit | | $4,208 | | $8,451 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.